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ABSTRACT
Allogeneic stem cell transplantation has been demonstrated to be curative in a wide variety of pediatric
malignant and nonmalignant diseases, and can be traced back over 50 years ago to the original report of
Thomas et al. HLA matched sibling donors have been the gold standard for pediatric recipients requiring
allogeneic donors for both nonmalignant and malignant conditions. However, only 25% of potential pediatric
recipients possesses an HLA-matched sibling donor, and the frequency is even less in those with genetic
nonmalignant conditions because of genetically affected other siblings within the family. Therefore, 75%
to 90% of potential pediatric recipients require alternative allogeneic donor cells for treatment of their
underlying conditions. Potential alternative allogeneic donor sources include unrelated cord blood donors,
unrelated adult donors, and haploidentical family donors. In this article we review the experience of both
unrelated cord blood donor and haploidentical family donor transplants in selected pediatric malignant
and nonmalignant conditions.
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plantsINTRODUCTION
Allogeneic stem cell transplantation has been
successful in the treatment of a variety of pediatric
malignant and nonmalignant conditions [1]. Unfor-
tunately, only 25% of eligible pediatric recipients
will have an HLA-matched sibling donor. Histori-
cally, unrelated adult donor HLA-matched alloge-
neic stem cell transplants have been utilized for
pediatric recipients who lack an HLA-matched
sibling donor. However, 2 other major allogeneic
donor sources are available, including unrelated
cord blood donors and haploidentical family
matched donors. In this manuscript, we review the
recent results of unrelated cord blood transplants
for pediatric nonmalignant conditions and haploi-
dentical family donor transplants for specific pediat-
ric malignant disorders.44CORD BLOOD AS AN ALTERNATIVE ALLOGENEIC STEM
CELL SOURCE FOR PEDIATRIC RECIPIENTS
It has been over 10 years since we and others dem-
onstrated the successful engraftment of pediatric re-
cipients with both malignant and nonmalignant
disease with related [2] and unrelated [3,4] cord blood
donor grafts. There are several advantages to utilizing
cord blood as a preferred allogeneic donor source
including: (1) little or no risk to the donor; (2) rapid
availability of processed donor source with prior char-
acterization; (3) extension of the donor pool because of
tolerance of 1-2 HLA mismatches of 6; (4) small cryo-
preserved volume with easy transport capability; (5)
low risk of infectious disease transmission of latent vi-
ruses such as CMV and EBV; (6) decreased severe
acute graft-versus-host disease (aGVHD) and chronic
GVHD (cGVHD); and (7) increased ethnic diversity
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some major limitations and/or concerns utilizing
cord blood donors include: (1) fixed number of cells
available with only a median of 1  109 total nucleated
cells, which results in increased graft failure; (2) less
clinical experience compared to unrelated adult donor
transplants; (3) lack of available donor immune cells
for post-CBT infusion; (4) few large-size and high-
quality units cryopreserved compared to the number
of registered unrelated adult donors (400,000 versus
8,000,000); and (5) slower hematopoietic engraftment
and immune reconstitution [5-9].
Cell dose, from a single cord blood unit, has been
significantly demonstrated to be associated with rapid-
ity of hematopoietic engraftment, In 2 large retrospec-
tive analysis, total nucleated cell count/kg of recipient
has been significantly associated with both myeloid
and platelet engraftment [10,11] (Figure 1A and B).
More recently, we have demonstrated that precryopre-
served CD34 cell dose/kg of recipient is significantly
associated with probability of overall survival (OS)
[12,13] (Figure 2A and B).
Although 1 of the unique advantages of utilizing
cord blood grafts as an alternative allogeneic stem
cell source is the ability to engraft across HLA dispa-
rate barriers, it now appears that the degree of HLA
disparity significantly influences engraftment and pos-
sibly OS. HLA mismatch at 2 or greater antigens com-
pared to \2 antigen mismatch following unrelated
cord blood transplantation in children is associated
with a significant decrease in survival and a significant
increase in treatment-related mortality (TRM)
[12,14].
There is still significant controversy over whether
to choose an unrelated cord blood graft versus an un-
related adult donor allograft [15]. Several retrospective
studies have been unable to identify a significant im-
provement in outcome or survival following unrelated
adult donor stem cell transplantation versus unrelated
cord blood transplantation. Netcord and European
Blood and Marrow Transplantation group (EBMT)
compared unrelated cord blood transplantation versus
unrelated adult donor allogeneic stem cell transplanta-
tion in children with acute leukemia and reported sim-
ilar 5-year event-free and OS rates [15,16]. More
recently, the CIBMTR and NCBP analyzed and com-
pared the results of unrelated donor cord blood
allografting with unrelated adult bone marrow trans-
plantation and demonstrated similar leukemia-free
survival in children with acute leukemia [14] (Figure 3).
Similarly, the risk of developing serious infections was
not statistically different in children following unre-
lated cord blood versus unrelated adult donor
allogeneic stem cell transplantation [17].
Future strategies to overcome or circumvent the
limitations of cell dose and HLA disparity following
unrelated cord blood transplantation in childreninclude the investigation of double cord blood trans-
plantation [18], reduced-intensity conditioning (RIC)
[19], ex vivo expansion of cord blood stem cells [20],
the use of cord blood T regulatory cells [21], cord
blood natural killer (NK) cells [22], and the overall
regenerative potential of cord blood stem cells [23].
As more unrelated cord blood units become cryopre-
served and available for alternative allogeneic stem
cell transplantation, newer investigations will be forth-
coming, where future results will assist pediatricians in
the decision of which alternative allogeneic stem cell
sources to choose from when their pediatric patient
Figure 1. (A) Kaplan-Meier estimates of the time to myeloid engraft-
ment after placental-blood transplantation, according to the dose of
leukocytes transfused. (Reprinted from Rubinstein P, Carrier C,
Scaradavou A, et al. Outcomes among 562 recipients from placen-
tal-blood transplants from unrelated donors. N Engl J Med.
1998;339:1569. Copyright  1998 Massachusetts Medical Society.
All Rights Reserved.) (B) Kaplan-Meier estimates of the time to
platelet engraftment after placental-blood transplantation, accord-
ing to the dose of leukocytes transfused. (Reprinted from Rubinstein
P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients
from placental-blood transplants from unrelated donors. N Engl J
Med. 1998;339:1569. Copyright  1998 Massachusetts Medical
Society. All Rights Reserved.)
46 M. S. Cairo et al.lacks an HLA matched sibling donor for a medical
condition that can be cured by allogeneic stem cell
transplant.
UMBILICAL CORD BLOOD TRANSPLANTATION IN
CHILDREN WITH NONHEMATOLOGIC MALIGNANCIES
Umbilical cord blood transplantation (UCBT) has
extended the availability of allogeneic hematopoietic
stem cell transplantation (HSCT) to patients who
would otherwise not be eligible for this curative
approach. Since the first successful UCBT from an
HLA-identical sibling in a child with severe Fanconi’s
Figure 2. (A) Cumulative proportion surviving after unrelated donor
UCB transplantation (n5 102): effect of CD34 cell dose (105/kilo-
gram recipient body weight). This research was originally published
in Wagner J., Barker J., DeFor T., et al. Transplantation of unrelated
donor umbilical cord blood in 102 patients with malignant and non-
malignant diseases: influence of CD34 cell dose and HLA disparity
on treatment-related mortality and survival. Blood. 2002;100:1616.
 the American Society of Hematology. (B) Probability of OS by
CD341 cell dose as determined by Kaplan-Meier and Cox’s regres-
sion multivariate analysis in patients receiving UCB transplantation.
CD341 at or .2.3  105 (———); CD341\2.3  105 (____) (P 5
.010,.2.3 versus\2.3  105/kg). This research was originally pub-
lished in Styczynski J, Cheung YK, Garvin J, et al. Unrelated donor
transplants: outcomes of unrelated cord blood transplantation in pe-
diatric recipients. Bone Marrow Transplant. 2004;34:129-136.anemia reported by Gluckman et al. in [24] 1989, the
number of UCB transplants from related and unre-
lated donors has increased dramatically, and we esti-
mate that more than 8000 patients have undergone
UCBT from unrelated donors to date for a variety of
genetic, hematologic, immunologic, metabolic, and
oncologic disorders.
The Eurocord registry, on behalf of the EBMT
and the Netcord banks, has collected data on 3372
related and unrelated cord blood transplants per-
formed in 373 transplant centers worldwide from
1988 to February 2007. Table 1 lists the patients re-
ported to Eurocord, transplanted with an unrelated
cord blood graft, according to age and diagnosis.
Most of the UCBT performed in children are for ma-
lignant disorders, but 460 transplants (28%) have been
already performed in children with nonmalignant dis-
orders. However, very few data analyzing risk factors
for outcomes after UCBT for nonmalignancies have
been reported.
To know the results and improve the outcomes of
UCBT in children with nonmalignant disorders, we
have analyzed the interaction of cell dose and HLA
in the cohort of children with all nonmalignant disor-
ders and performed specific analyses for more frequent
diagnosis.
Interaction between Cell Dose and HLA in
Children with Nonmalignant Disorders
Multicenter, single-institution, and consortium
studies have shown that unrelated donor UCBT in
children, most with malignant disorders, have demon-
strated the profound impact of cell dose and HLA on
engraftment, adverse transplant-related events and
survival and relapse [10-13,25,26].
We developed the hypothesis that cell dose and
number of HLA disparities will have an impact on
the outcomes of UCBT in children with nonmalignant
disorders. With this aim, we have studied 268 children
with nonmalignant disorders following an unrelated
cord blood transplant from 1994 to 2005. The median
age of patients at UCBT was 5 years (range 3 months
to 10 years), and the median follow-up time was 29
months. Recipient’s CMV serology prior to transplant
was positive in 52% of the patients. The diagnosis was
bone marrow failure syndrome in 48% (69% Fanconi
disease, 18% acquired SAA, 13% congenital BMFS),
primary immunodeficiency in 30%, and a hereditary
metabolic disorder in 22% of patients.
Only 17% were classified as identical for HLA class I
antigens and class II allelic typing, whereas 43% had 1
HLA difference, 36% had 2 HLA differences, and the
remainder had 3 HLA differences. For patients with 1
HLA mismatch, 72% had a class I difference and 28%
a class II difference. For patients with 2 HLA differ-
ences, 44% had 2 class I differences, 3% had 2 class II
differences, and 53% 1 class I and 1 class II difference.
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases 47Figure 3. Probability of leukemia-free survival after bone marrow and cord blood transplantation adjusted for disease status at transplantation.
(Reprinted from Eapen M, Rubinstein P, Zhang M, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow
in children with acute leukaemia: a comparison study. Lancet 2007;369:1947-1954, with permission from Elsevier.)The median number of nucleated cells (NCs) infused
was 7.6  107 NC/kg (range: 0.8-66  107 NC/kg).
With respect to GVHD prophylaxis, 53% received
the combination of cyclosporine (CsA) and steroids. A
variety of conditioning regimens were reported ac-
cording to the disease and transplant center, but
many patients received a busulfan based regimen.
The utilization of fludarabine was present in 30% of
the cases. Anti-T immunotherapy was given before
day 0 to 84% of the recipients.
At day 100, the cumulative incidence (CI) of neu-
trophil recovery was 69.3% and CI of platelet recovery
was 50%. Both outcomes were significantly correlated
with the median number of cells infused (P\ .0001).
HLA was also an important factor associated with neu-
trophil recovery, with a statistical difference between0 and 1 and $2 HLA mismatches (P 5 .046). The
role of HLA mismatching was abrogated by increasing
cell dose because patients given a higher cell dose
(.3.5  107/kg) even with 0, 1, 2, and 3 HLA dispar-
ities had a higher probability of recovery compared to
those given lower cell dose with the same disparities.
There was no correlation between neutrophil recovery
and class of HLA mismatching (class I or class II, or
HLA-A, -B, or -DRB1).
The CI of aGVHD grade II-IV was 32% and grade
III-IV 18%, and was only associated with the num-
ber of HLA incompatibilities (P 5 .0029). The CI
of cGVHD was 24% and was also associated with
the number of HLA incompatibilities (P 5 .01). The
probability of OS at 100 months was 49%. OS was
influenced by cell dose and by the number of HLATable 1. Number of Unrelated CBT Reported to Eurocord Registry According to Diagnosis and Recipient Age
Diagnosis Children (#16 Years, n 5 1609) Adults (.16 Years, n 5 1136)
Acute lymphoblastic leukemia 579 (36%) 269 (23.7%)
Acute myelogenous leukemia 257 (16%) 356 (31.3%)
Secondary acute leukemia 38 (2%) 63 (5.5%)
Myelodysplastic syndrome 120 (7.5%) 97 (8.5%)
Chronic myelogenous leukemia 40 (2.5%) 119 (10.5%)
Chronic lymphocytic leukemia — 16 (1.4%)
Hodgkin/non-Hodgkin lymphomas 31 / – (2%) 97 / 32 (11.4%)
Myeloma — 20 (1.8%)
Solid tumors 9 (0.7%) 5 (0.4%)
Histiocytosis 60 (3.5 %) 1 (0.1%)
Congenital and acquired bone marrow failure syndromes 157 (9.5%) 50 (4.4%)
Hemoglobinopathies 7 (0.5%) —
Primary immunodeficiencies 170 (10%) 1 (0.1%)
Metabolic diseases 126 (8%) 5 (0.4%)
Other disease 11 (0.8%) 5 (0.4%)
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\3.5  107 NC/kg at infusion and a 2-3 HLA-mis-
matched transplant had \10% survival. Increasing
cell dose partially abrogated the effect of HLA mis-
matches. There was no statistical difference between
the groups who received a cell dose of .3.5  107
NC/kg with a 0, 1, 2, or 3 HLA-mismatched UCBT
(Figure 4) (unpublished Eurocord data).
Thus, patients with a nonmalignant disease must
receive a higher cell dose to obtain engraftment com-
pared to patients with a malignant disease. The mini-
mum UCB cell dose should not be below 4.9  107
NC/kg at collection and 3.5  107 NC/kg at infusion.
In nonmalignant disorders, HLA mismatching played
a major role in engraftment, GVHD, TRM, and sur-
vival, which was abrogated by increasing cell dose. A
CB graft containing 2 or more HLA disparities with
a cell dose inferior to 3.5  107 NC/kg should be
avoided. Experience of double cord blood transplanta-
tion in nonmalignant disorders is still too limited to al-
low routine recommendation of this type of transplant,
and is currently under investigation.
Fanconi Anemia Disease
In the group of children with bone marrow failure
syndromes the majority of UCBT recipients have
a Fanconi anemia (FA) phenotype. We have analyzed
risk factors associated with outcome after unrelated
UCBT in 93 FA patients. Median age at transplanta-
tion was 8.6 years (1-45). The units transplanted
were HLA-A, -B, and -DRB1 identical in 12 cases,
1 HLA difference in 35 cases, and 2 or 3 HLA differ-
ences in 45 cases. The median number of NC and
CD341 cells infused of recipient weight was 4.9 
107/kg and 1.9  105/kg, respectively. Participating
centers selected the conditioning regimen of their
choice; in 57 patients (61%), the majority of the condi-
tioning regimens included fludarabine. CI of neutro-
phil recovery was 60% 6 5% at day 160. In
a multivariate analysis, a fludarabine-containing pre-
parative regimen and NC number infused $4.9 
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Figure 4. OS in 268 patients with nonmalignant disorders according
to cell dose infused (107/kg) and HLA differences.107/kg were associated with a higher probability of
neutrophil recovery. CI of grade II-IV aGVHD and
of cGVHD were 32% 6 5% and 16% 6 4%, respec-
tively. The 3-year probability of survival was
40% 6 5%. In univariate analysis, favorable factors
associated with survival were: age younger than 16
years at transplant (P 5 .05), HLA compatibility
(P 5 .009),\20 RBC transfusions before transplanta-
tion (P 5 .008), recipient’s negative CMV serology
(P 5 .0003), use of Fludarabine in the conditioning
regimen (P 5 .01) .4.9  107 nucleated cells/kg in-
fused (P 5 .04). In multivariate analysis, these latter
3 factors remained statistically significant [27]. In
conclusion, factors easily modifiable such as donor se-
lection and a Fludarabine containing regimen can
considerably improve survival in FA patients given
an UCBT. These data are the basis for designing pro-
spective protocols.
Severe Primary Immunodeficiencies
Outcomes of 93 unrelated UCBT in children with
severe primary immunodeficiencies (SPID) reported
to Eurocord by 40 centers were analyzed (J. Ortega
on behalf of Eurocord; unpublished data). Median
age was 0.9 years (range: 0-26), and median weight
8 kg (3-39). Diagnosis included severe combined im-
munodeficiency (n 5 61), Wiskott-Aldrich syndrome
(n 5 20), and other (n 5 12). Fifty-six patients were
matched or had 1-HLA difference with the CB unit.
The median number of NC infused was 8.3  107/kg
(0.1-94), and the median CD341 cell number
3.4  105/kg (0.4-33). Conditioning regimens varied
according to disease and transplant centers protocol.
In fact, 11 patients (12%) did not receive any condi-
tioning, 44 (46%) Bu/Cy, 24 (26%) a Fludarabine con-
taining regimen, 7 (8%) irradiation-based regimen,
and 7 (8%) an other regimens. Seventy-four patients
received cyclosporine/steroids as GVHD prophylaxis.
CIs for neutrophil and platelet recoveries were 85%
and 77%, respectively. CIs for acute grades II-IV and
cGVHD were 41% and 23%, respectively. TRM at
2 years was 31%. Survival at 2 years was 68% overall;
78% if patient/CB unit were matched or had
1 HLA-disparity, and 58% with 2 to 3 HLA differ-
ences (multivariate analysis, P 5 .04).
Metabolic Diseases: Hurler Syndrome
Small series of patients with very encouraging re-
sults have been reported in children with Krabbe’s
and Hurler’s disease [28,29]. Hurler’s syndrome
(HS), the most severe form of mucopolysaccharidosis
type-I, causes progressive deterioration of the central
nervous system and death in childhood. Hematopoi-
etic allogeneic-stem cell transplantation before the
age of 2 years halts disease progression and prolongs
life. Graft failure and mixed chimerism (40%-50%)
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blood transplants are suggested to be a good alternative
option for bone marrow; however, little is known about
risk factors for outcomes after UCBT for this disease.
We have analyzed 93 children with HS given an
UCBT from 1995 and 2007 reported to Eurocord or
transplanted at Duke University. Median age at
UCBT was 1.3 (0.2-4) years, and median follow up
was 24 (3-140) months. The donors were HLA-identi-
cal (HLA-A and -B by low resolution and HLA-DRB1
by high resolution) in 13 cases (16%) and incompatible
in 67 cases (84%: most with 1 [54%] and 2 HLA dispar-
ities [26%]). The median NC dose/kg and CD341/kg
at infusion were, respectively, 7.2 (2-22)  107 and 2.3
(0.5-17)  105. With the exception of 5 patients, all
received a busulfan/cyclophosphamide (1fludarabine:
n5 6) regimen. All patients received ATG or Campath
(n5 4). Median days to neutrophil and platelet recov-
ery were 22 (10-46) and 35 (13-82) days, respectively.
Mixed chimerism was found in only 6%. All patients
had normal enzyme levels after engraftment. In multi-
variate analyses for neutrophil recovery, a CD341 dose
of.2.3 105/kg (hazard ratio [HR]5 2.0; P5 0.015)
was associated with increased probability of recovery.
aGVHD (grade II-IV) was observed in 27%, whereas
cGVHD was seen in 10% at 2 year. Two years OS
and disease-free survival (DFS) were 78% and 70%, re-
spectively. For 2 year OS, time from diagnosis to
UCBT lower than 6 months was associated with better
OS (94% for those children transplanted earlier and
70% for those transplanted later (P5 .04). Transplan-
tation improved somatic features of HS. More detailed
long-term follow up is currently ongoing. In conclu-
sion, outcomes following UCBT for Hurler’s syn-
drome are encouraging. UCB is a good alternative
allogeneic stem cell source to transplant children
with HS, and is associated with low frequencies of
mixed chimerism. Earlier transplantation and higher
cell dose are associated with better outcomes after
UCBT for HS patients [30].
Cord Blood Transplantation for Patients with
Hemoglobinopathies
Very few patients with Thalassemia (thal) or sickle
cell disease (SCD) have been transplanted with an un-
related cord blood transplantation. Seven children
with hemoglobinopathies have been reported to Euro-
cord. Clinical data is available in 4 children, 2 with thal
and 2 with SCD. All 4 patients are alive and well with-
out transfusion dependency.
A specific analysis has been performed and pub-
lished for 44 children with thal and SCD following
a related UCBT [31]. We have updated this analysis
and confirmed that all 63 patients are alive, and the
5-year DFS is 78% in the 44 thal patients, and 94%
for the 19 SCD patients. The absence of methotrexate
(MTX) in the GVHD prophylaxis and the use offludarabine in the conditioning regimen were the
most important factors associated with increased
DFS. The Eurocord group is currently performing
a comparative study between bone marrow and cord
blood in HLA identical sibling transplants for children
with thal or SCD.
In summary, these results demonstrated that unre-
lated UCBT can be considered as a source of alloge-
neic stem cells for transplantation for those children
with genetic and metabolic diseases, who need an
HSCT and who lack an HLA identical sibling donor.
Outcomes are associated with patient, disease, and
transplant characteristics. Therefore, better patient se-
lection and factors easily modifiable such as cord blood
unit selection and changes in conditioning regimens or
GVHD prophylaxis can improve outcome. Currently,
there is no study comparing results of UCBT and
other HSCT in children with nonmalignant disorders,
but based on the studies comparing unrelated cord
blood with bone marrow in children with malignant
disorders [32] we can strongly suggest that the search
for an UCB unit should be started simultaneously as
for BM unrelated donors also, in children with nonma-
lignant disorders. Because HLA and cell dose are also
very important in this setting, cord blood banks should
increase their inventories, with the aim of finding more
closely matched CB grafts.
HAPLOIDENTICAL TRANSPLANTS FOR CHILDHOOD
HEMATOLOGIC MALIGNANCIES
Haploidentical HSCT has been limited by obsta-
cles intrinsic to alloreactivity between unmatched
donor-recipient pairs: graft failure, GVHD, posttrans-
plant lymphoproliferative disease (PTLPD), and pro-
longed immunodeficiency [33-35]. Advances in graft
engineering, supportive care, increased usage of pe-
ripheral blood stem cell (PBSC) grafts with high stem
cell content, and observations that a graft-versus-
leukemia (GVL) effect may exist in killer immunoglob-
ulin-like receptor (KIR) mismatched donor-recipient
pairs have resulted in improved outcomes, making it
an attractive, potentially curative option for those
patients who either lack a matched related donor or
who do not have time to wait for an unrelated donor
to become available. Mismatched family member
(MMFM) donors are highly motivated and readily
available throughout the transplant process for initial
and subsequent product donation, can be rapidly
evaluated for product donation, and may provide
an immunologic GVL effect if the donor-recipient
pair are mismatched for KIRs [36]. Donor evalua-
tion, performed at the recipient’s transplant center,
avoids conflicts with another donor center and the
time for an unrelated donor search.
T-lymphocyte depletion of grafts is typically
necessary to reduce the risk of severe GVHD.
50 M. S. Cairo et al.Historically, methods of T cell depletion (TCD) were
inadequate, resulting in GVHD, or excessive, resulting
in graft failure and prolonged immunosuppression.
Newer, more precise graft engineering strategies allow
more rigorous control of graft content of hematopoi-
etic progenitor or immunologic cell populations. Typ-
ically, CD341 selection using immunomagnetic
columns, resulting in a 5-log CD31 depletion of the
graft, eliminates posttransplant GVHD prophylaxis
requirements [37]. These highly purified grafts, con-
taining megadoses of CD341 hematopoietic stem cells
(.10  106 CD341/kg) and essentially no B cells,
overcome engraftment barriers and make PTLPD
rare [38]. One study using megadoses of highly puri-
fied CD341 hematopoietic cells demonstrated full do-
nor engraftment in all 43 patients treated [39]. No
patient developed GVHD. With a median follow-up
of 18 months, 12 of the 43 patients were alive in remis-
sion. A subsequent trial of haploidentical HSCT in
104 patients received CD34-positive selected grafts
with no pharmacologic GVHD prophylaxis [40].
aGVHD occurred in 8 of 100 evaluable patients;
cGVHD occurred in 5 of 70 assessable patients. At
a median of 22 months, event-free survival was 48%
for AML and 46% for ALL patients transplanted in re-
mission. A recent trial of 34 children with leukemia
who received an ablative regimen reported an actuarial
survival of 26% [41].
Other investigators are employing a CD3
depletion strategy with OKT3 on immunomagnetic
columns to manufacture a graft containing immuno-
logically active cells such as NK cells, monocytes, den-
dritic cells, and CD342 hematopoietic precursors [42].
This process results in grafts with a greater T cell con-
tent (3.5-log depletion) compared to CD341 selection,
hastening engraftment and immune reconstitution.
CD3-depleted grafts have a greater B cell content,
leading to increased risk of PTLPD. However, pro-
phylaxis with rituximab or with donor-derived EBV-
specific cytotoxic T-lymphocytes while monitoring
for EBV reactivation may prevent this complication.
In 20 children receiving CD3-depleted grafts follow-
ing an ablative TBI-containing conditioning regimen,
all evaluable patients engrafted at a median of 13 days;
none developed grade III-IV aGVHD [43]. At 1 year
posttransplantation, DFS is 45%. In a concurrently
treated group of 25 patients with refractory disease
or undergoing second allotransplantation who re-
ceived CD3-depleted grafts after a reduced intensity
regimen, all but 3 engrafted at a median of 10 days
posttransplantation [44]. Only 8% developed grade
III-IV aGVHD and 40% survive in remission 1 year
posttransplantation.
Chinese investigators have recently described their
experience in MMFM HSCT using non-TCD cyto-
kine-primed marrow and peripheral blood grafts, em-
ploying in vivo T cell depletion with ATG [45,46]. In 1study describing 171 patients, all were engrafted with
23% developing grade III-IV aGVHD and 47% devel-
oping cGVHD, leading to a 2-year DFS of 68% and
42% in standard-risk and high-risk patients, respec-
tively. A subsequent report of 239 patients described
comparable rates of cGVHD, TRM, relapse, and sur-
vival in non-TCD MMFM graft recipients (n 5 135)
compared to matched sibling recipients (n 5 158).
All engrafted with 40% of MMFM recipients develop-
ing grade III-IV aGVHD. These trials, in a relatively
well-defined, homogenous population suggest that
in vivo T cell depletion may be sufficient in some
circumstances.
Alternate strategies to reducing GVHD risk after
MMFM HSCT include the induction of tolerance.
One strategy cocultured recipient antigen-presenting
cells and T-replete donor marrow in the presence
of agents to selectively inactivate host-reactive T
cells [47]. All 12 received a TBI-based regimen and
a bone marrow graft treated as described above. Only
3 patients developed GVHD despite posttransplant
immunosuppression, and 5 remain alive in remission
at 4.5 to 29 months after transplantation.
Recently, clinicians have employed reduced-inten-
sity or nonmyeloablative conditioning regimens in an
attempt to reduce toxicity, especially in older patients
and those with comorbidities. Haploidentical HSCT
has been successfully performed with engraftment
and long-term disease responses in patients with he-
matologic malignancies, including those with refrac-
tory disease [43,44]. Of 49 patients receiving ablative
regimens with mycophenolate with or without cyclo-
sporine, 94% were engrafted [48]. Treatment-related
mortality was 10% and 8% had severe GVHD. The
1-year survival rate was 31%; the 19 standard-risk
patients had a 63% 1-year survival rate, demonstrating
that nonablative regimens result in favorable
outcomes, particularly for patients transplanted in
remission.
Delayed engraftment and graft failure are concerns
after transplantation of TCD grafts. TCD shifts the
immunologic balance in favor of the host, augmenting
the risk of graft rejection. Time to neutrophil engraft-
ment has been abbreviated with reduced intensity con-
ditioning regimens, less intensive TCD, growth factor
administration, and PBSC grafts containing mega-
doses of hematopoietic precursors. Recent reports
confirm rapid neutrophil engraftment in recipients of
MMFM grafts, in contrast to the delayed recovery af-
ter cord blood HSCT [43,44,49]. Rapid engraftment
shortens the neutropenic period, reduces blood prod-
uct transfusions, and curtails hospitalizations. Weekly
peripheral blood chimerism monitoring can identify
early disease recurrence or graft rejection [47,50,51].
Improved TCD methodologies have dramatically
reduced the incidence of severe GVHD. In fact, calci-
neurin inhibitors, which are associated with significant
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases 51toxicities, can be omitted [49,51]. For grafts partially
depleted of CD31 cells, single agents that have fewer
side effects such as mycophenolate mofetil (MMF)
can be used [43,44]. Immune reconstitution is more
rapid, reducing the risks of infectious complications
in patients receiving less intense pharmacologic immu-
nosuppression. In fact, with low incidences of severe
GVHD, permissive GVHD may be allowed in an ef-
fort to reduce relapse rates in high-risk patients.
Delayed immune reconstitution remains a signifi-
cant challenge. One recent study demonstrated that im-
mune reconstitution may be hastened in recipients of
conditioning regimens omitting TBI or ATG [52]. In
this group of heavily pretreated patients with refractory
malignancies, CD31 lymphocytes recovered more rap-
idly than was observed in patients with standard-risk he-
matologic malignancies receiving an ablative
conditioning regimen containing TBI and ATG. This
observation may be because of the preservation of T-
lymphocyte reconstitution in the absence of ATG and
the thymic protection afforded by omitting TBI. Fi-
nally, infusion of nonalloreactive CD31 cells after hap-
loidentical transplantation has resulted in acceptable
GVHD rates with improved immune reconstitution
[53]. Serial monitoring of immunologic recovery is im-
portant to ascertain infection risk; rapid high-through-
put methodologies have been developed to expedite
this testing [54]. Patients should be serially monitored
for EBV, CMV, and adenovirus DNA reactivation so
that preemptive therapy can be initiated early [55-57].
Additional donor cellular product infusions may be
required after transplantation; haploidentical donors
are continuously available for timely donation. Stem
cell boosts have restored hematopoietic graft function
without conditioning in cytopenic patients with donor
cell engraftment after transplantation [58]. Donor
lymphocyte infusions (DLIs) can treat early disease
recurrence, restore donor hematopoiesis, and treat in-
fections. The risk of GVHD can be reduced by admin-
istering DLIs with low CD31 content [59].
Donor-recipient NK cell alloreactivity in KIR
mismatched donor-recipient pairs may result in lower
relapse rates, particularly in patients with myeloid ma-
lignancies, or may hasten engraftment and immune re-
constitution [60,61]. Unpurified NK cell infusions
from haploidentical donors for patients with cancer re-
ceiving an intense immunoblative chemotherapy regi-
men have been performed safely with in vivo expansion
of donor NK cells with administration of interleukin-2
[62]. Other investigators have been able to isolate
highly purified CD561 hematopoietic cells from
unstimulated leukapheresis products from healthy do-
nors, allowing for posttransplant infusions of NK cells
to further decrease relapse risks [63].
Investigators demonstrated that prior exposure
to noninherited maternal antigens (NIMA) during
pregnancy may lead to feto-maternal microchimerismwith the induction of tolerance [64]. Published studies
have demonstrated acceptable engraftment with lower
rates of aGVHD in recipients of sibling or haploident-
ical T cell replete grafts in which the donor and recip-
ient are mismatched for NIMA compared to those
mismatched for noninherited paternal antigen
(NIPA) [65-70]. An IBMTR analysis demonstrated
that recipients of grafts from NIMA mismatched sib-
lings result in a lower rate of aGVHD and cGVHD
with similar rates of graft failure compared to NIPA
mismatched siblings; when compared to parental do-
nor HSCT, TRM was significantly lower for haploi-
dentical sibling HSCT, mismatched for NIMA [71].
Haploidentical HSCT is a promising alternative
treatment for patients requiring transplantation. Re-
cent advances have resulted in rapid neutrophil and
platelet engraftment, tolerable GVHD rates, and the
potential to induce an alloreactive GVL effect in
KIR mismatched donor-recipient pairs. However, de-
layed immune reconstitution and disease recurrence
remain challenges. Future research in this field must
define a safe platform for haploidentical HSCT while
hastening immune reconstitution and reducing
relapse. With improvements in graft engineering
methodologies and the refinement of posttransplant
immunotherapies, haploidentical HSCT may be in-
creasingly used with near-universal donor availability
allowing nearly all patients to undergo transplantation.
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